HSBC lowered the firm’s price target on BioNTech to $90 from $115 and keeps a Hold rating on the shares. The analyst says with a broad range of pipeline assets to offset the COVID-19 revenue cliff, BioNTech’s research and development productivity “becomes crucial.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BNTX: